PureTech Health to Present at Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Feb 21, 2019--PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced two presentations at upcoming investor conferences. Daphne Zohar, co-founder and chief executive officer, will present at the SVB Leerink Global Healthcare Conference in New York on Friday, March 1, at 11:30 AM EST. Additionally, Joep Muijrers, PhD, chief financial officer, will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Tuesday, March 12, at 8:00 AM EST. Webcasts of both presentations will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.
About PureTech Health PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insights into the connection between these systems and the resulting role in diseases that have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative therapies with a capital efficient R&D model across its Affiliates and its Internal labs. PureTech’s Affiliates include seven clinical-stage platforms with two product candidates that have been filed with the US Food and Drug Administration (FDA) for review and other novel pre-clinical programs. These Affiliates are developing ground-breaking platforms and therapeutic candidates in collaboration with some of the world’s leading experts.
PureTech’s Internal research and development is centered on tissue-selective immunomodulation for the treatment of oncology, autoimmune, and CNS-related disorders, with a near-term focus on targeting newly-discovered, foundational immunosuppressive mechanisms in oncology and novel approaches that harness the lymphatic infrastructure.
Forward Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190220006017/en/
Allison Mead Talbot
+1 617 651 3156
+1 857 559 3397
KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: PureTech Health plc
Copyright Business Wire 2019.
PUB: 02/21/2019 02:00 AM/DISC: 02/21/2019 02:01 AM